



# International Journal of Advanced Chemistry Research

ISSN Print: 2664-6781  
 ISSN Online: 2664-679X  
 IJACR 2024; 6(1): 120-128  
[www.chemistryjournals.net](http://www.chemistryjournals.net)  
 Received: 05-03-2024  
 Accepted: 07-04-2024

**Shaimaa Abdulrahman Abdulhassan**  
 Martyr Mohammed Baqer Al-Hakim Hospital, Baghdad, Iraq

**Wasan T Al-Rubayee**  
 Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq

**Noor Al-Huda Mohammed Idris**  
 Al Karama Teaching Hospital, Baghdad, Iraq

**Corresponding Author:**  
**Shaimaa Abdulrahman Abdulhassan**  
 Martyr Mohammed Baqer Al-Hakim Hospital, Baghdad, Iraq

## Obesity, insulin resistance, and hormonal perturbations in Iraqi women

**Shaimaa Abdulrahman Abdulhassan, Wasan T Al-Rubayee and Noor Al-Huda Mohammed Idris**

**DOI:** <https://doi.org/10.33545/26646781.2024.v6.i1b.176>

### Abstract

**Background:** Obesity and increased weight are related to polycystic ovarian syndrome (PCOS) progression and exacerbate insulin resistance (IR).

**Aims of the study:** This research aimed to assess the potential impacts of BMI and IR on the functions of the pituitary-ovary and the pituitary-thyroid axis by assessing the follicle-stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH), thyroid stimulating hormone (TSH), Triiodothyronine (T<sub>3</sub>), Thyroxine (T<sub>4</sub>) and prolactin serum levels in the overweight and the obese PCOS groups.

**Methodology:** From May to December 2023, Martyr Mohammed Baqer Al-Hakim Hospital in Baghdad City, Iraq, conducted this prospective study. The individuals were divided into three BMI groups: 40 in the normal weight control group (BMI < 25 kg/m<sup>2</sup>), 30 in the overweight group (BMI ≥ 25 kg/m<sup>2</sup>), and 30 in the obese PCOS group (BMI ≥ 30 kg/m<sup>2</sup>). On days two or three of menstruation, blood was drawn. Electrochemiluminescence measured basal hormones.

**Result:** Obese PCOS patients had higher levels of LH, LH/FSH, prolactin, E2, and TSH, and decreased levels of FSH, T<sub>3</sub>, and T<sub>4</sub> compared to the normal weight group ( $p < 0.05$ ). Additionally, the overweight group had considerably ( $p < 0.05$ ) lower LH, FSH, and E2 levels than the normal weight group. LH/FSH, prolactin, T<sub>3</sub>, T<sub>4</sub>, and TSH were not significantly different ( $p > 0.05$ ) between groups. In the overweight group, BMI was associated with FSH ( $r = -0.39$ ,  $P = 0.03$ ). The obese PCOS group had a comparable LH association ( $r = -0.52$ ,  $P = 0.02$ ). Obese PCOS patients had a BMI-HOMA-IR association ( $r = 0.42$ ,  $P = 0.02$ ).

**Conclusion:** Our research shows that BMI decreases gonadotropin release in overweight and obese PCOS patients. However, IR does not inhibit/stimulate the pituitary-ovary or pituitary-thyroid axes.

**Keywords:** Polycystic ovarian syndrome, insulin resistance, obesity, body mass index, hormones

### Introduction

A body mass index (BMI) beyond 30 kg/m<sup>2</sup> indicates obesity, characterized by an abundance of body fat. BMI is frequently employed as a reliable measure of adiposity in epidemiological investigations (Deurenberg *et al.*, 1991) [15]. The World Health Organization (WHO) estimated that 15% of women worldwide were obese in a report that was released in 2016 (WHO, 2016) [61]. Furthermore, 25.40% of women in the Middle East who were of childbearing age were obese (Okati-Aliabad *et al.*, 2022) [44]. This troubling trend is observed in Iraq, where 35.2% of women are obese (Jasim *et al.*, 2018) [31]. No matter how they conceive, obese women exhibit worse reproduction rates (Elia *et al.*, 2015) [21], and rising BMI is coupled with worse fertility diagnosis (Supramaniam *et al.*, 2018) [55]. The risk of several diseases is exacerbated by obesity, especially insulin resistance (IR) (Sayn *et al.*, 2020) [51]. The relationship between obesity and inflammatory processes in skeletal muscles, adipose tissues, and the pancreas has been documented (Kawai *et al.*, 2021) [32]. Besides this, immune cells could be active in the inflammation linked to obesity, which is significant since it may function as a biological connection between IR and obesity (Wu & Ballantyne, 2020) [63]. However, adipose tissues produce more significant glycerol, hormones, non-esterified fatty acids, and cytokines that may contribute to IR development (Wondmkun, 2020) [62]. Obese women have a poorly functioning hypothalamic-pituitary-ovarian (HPO) axis (Chen *et al.*, 2022) [8] and they typically experience menstrual irregularity that ends in infertility and anovulation (Mikhael *et al.*, 2019) [38].

Pituitary gonadotrophs synthesize follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which they employ for ovulation (Choi & Smitz, 2014) <sup>[19]</sup>. One etiology for the general impaired fertility in obese women is that both LH and FSH are routinely determined to be diminished, with a related decline in progesterone and estrogen generation by the ovary following ovulation (Jain *et al.*, 2007) <sup>[29]</sup>. The endocrine condition influencing females of childbearing age is polycystic ovarian syndrome (PCOS) (Norman *et al.*, 2007) <sup>[42]</sup>. In compliance with the clinical protocols of the Rotterdam, the incidence of PCOS in females of childbearing age in numerous countries was reported to be from 5 to 13% (Bozdag *et al.*, 2016) <sup>[3]</sup>. In contrast, Iraqi women had a PCOS incidence of around 33% (Mousa & Al Joborae, 2020) <sup>[40]</sup>, which is greater than in other nations. Indeed, a principal reason for PCOS, IR, is typically present in concerned PCOS women (Zhao *et al.*, 2023) <sup>[65]</sup>. Fundamental processes for the pathogenesis of PCOS would include the metabolic effects of IR and hyperinsulinemia on steroidogenic and reproductive processes (Barber *et al.*, 2019) <sup>[2]</sup>. Obesity and increased weight are related to the development of PCOS as they exacerbate hyperandrogenism and menstrual irregularities (Itriyeva, 2022) <sup>[28]</sup>. Between 6 and 100% of PCOS females are obese or overweight (Lim *et al.*, 2012) <sup>[33]</sup>. This research aimed to assess the potential impacts of BMI and IR on the functions of the pituitary-ovary and the pituitary-thyroid axis by assessing the FSH, LH, E2, prolactin, TSH, T<sub>3</sub>, and T<sub>4</sub> blood levels in the overweight and obese PCOS group.

### Methodology

Women were enlisted at the Martyr Mohammed Baqer Al-Hakim Hospital, Baghdad, Iraq, from May 2023 to December 2023. According to BMI, the subjects were split into three groups: Forty in the normal weight control group (BMI < 25 kg/m<sup>2</sup>), Thirty in the overweight group (BMI ≥ 25 kg/m<sup>2</sup>), and Thirty in the obese PCOS group (BMI ≥ 30 kg/m<sup>2</sup>). Further, every woman was provided with informed consent. For the obese PCOS group, the subjects aged 19 to 45 years; for the overweight group, from 21 to 45 years; and for the normal weight group, from 18 to 44 years. PCOS females were identified employing the Rotterdam criteria (ESHRE & ASRM, 2004) <sup>[22]</sup>. Females with the following causes were eliminated from participating in the study: endometriosis, uterine fibroid, cancer, adrenal hyperplasia, Cushing syndrome, adrenal virilism, androgen-secreting

tumour, hyper- and hypothyroidism, diabetes, hyperprolactinemia, smoking, and being drinking. The blood draw occurred on days two or three of the menstrual cycle. Venous blood samples (10 mL) were gathered by puncturing women's veins, converted to plain tubes, and centrifuged at 402×g to separate serum. The samples were deep-frozen till hormonal analysis at -20 °C. Serum glucose level was assessed using the kit (Glucose MR, Linear chemicals, Barcelona, SPAIN). Electrochemiluminescence was employed to quantify basal hormones (Cobas E411 Immunoassay System, ROCHE, Switzerland). The body mass index was calculated using the equation dividing the weight by the square of the height, and the HOMA-IR was also calculated using the equation by the insulin concentration multiplied by the glucose concentration divided by 405.

### Statistical analysis

SPSS for Windows, version 26, was employed to evaluate the findings (SPSS Inc. Chicago, Illinois, United States). The normality distribution of all variables was analyzed. The findings were tabulated as mean and standard deviation (SD). Following the ANOVA test, the Post Hoc test was employed. Pearson correlation was implemented to investigate the relationship degree between various parameters.  $p < 0.05$  was designated as the threshold for significance.

### Results

#### Socio-demographic characteristics of the study groups

In a study comparing normal-weight women, overweight women, and obese women with polycystic ovary syndrome (PCOS), it was found that mean age did not show statistically significant differences between the three groups, with mean ages of 33.65±6.54 and 33.63±5.62. and 33.33±6.40, respectively, with a P value of 0.90. However, there were statistically significant differences in body mass index (BMI) with normal-weight women recording a value of 22.21±2.31, overweight women 27.32±1.39, and obese women with PCOS 35.93±6.27, with a P value equal to 0.00. Also, the HOMA-IR showed significant differences between groups with readings of 2.14±0.40, 3.91±1.73, and 7.07±2.95 for normal-weight, overweight, and obese women with PCOS with a P value of 0.00. Noting a significant increase in insulin resistance consistent with increases in body mass index.




Fig 1: General characteristics of the studied groups

**Table 1:** General characteristics of the studied groups.

	Normal-weight (N=40)	Overweight (N=30)	Obese PCOS (N=30)	P
Age (year)	33.65±6.54 a	33.63±5.62 a	33.33±6.40 a	0.90
BMI (Kg/m <sup>2</sup> )	22.21±2.31 a	27.32±1.39 b	35.93±6.27 c	0.00
HOMA-IR	2.14±0.40 a	3.91 ±1.73 b	7.07±2.95 c	0.00


### The difference between the levels of sex hormones and thyroid hormones between the case group and the control group

The study showed highly statistically significant differences in the levels of some hormones when compared between normal-weight, overweight, and obese women with polycystic ovary syndrome (PCOS). Luteinizing hormone (LH) levels were significantly higher in obese women with PCOS (12.04±3.13 mIU/mL) compared to the other two groups (8.63±3.20 mIU/mL for normal weight and 7.00±1.95 mIU/mL for overweight). With p value < 0.001. Significant decreases in follicle-stimulating hormone (FSH) levels were also recorded in the second group (4.99±1.41 mIU/mL compared to the first and third (7.05±1.64 mIU/mL and 6.18±2.04 mIU/mL, respectively) with a p-value < 0.001. While the ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) was significantly higher in obese women with PCOS syndrome

(2.00±0.82) compared to normal weight (1.22±0.43) and overweight (1.46±0.73) with a p-value < 0.001. Also, an increase in prolactin levels was observed with weight gain, recorded (10.37±4.85 ng/mL) in normal-weight women, (13.87±5.41 ng/mL) in overweight women, and (18.84±3.91 ng/mL) in obese women with PCOS., with p-value < 0.001. While there was a significant difference in estradiol (E2) levels, which decreased in overweight women (297.67±97.65 pMol/L) compared to normal weight (402.00±112.16 pMol/L) and obese women with PCOS (417.05±130.07 pMol/L) with a p-value < 0.001. Thyroid hormones T<sub>3</sub> and T<sub>4</sub> did not show statistically significant differences between the three groups with p at 0.52 and 0.08, respectively. However, TSH levels increased dramatically in obese PCOS patients (2.32±0.93 mIU/L) compared to the other two groups (1.40±0.72 mIU/L for normal weight and 1.74±0.51 mIU/L for overweight), the p-value was < 0.001.

**Table 2:** Basal serum levels of hormones in normal-weight, overweight, and obese PCOS.

	Normal-weight (N=40)	Overweight (N=30)	Obese PCOS (N=30)	P value
LH (mIU/mL)	8.63±3.20	7.00±1.95	12.04 ±3.13	<0.001
FSH (mIU/mL)	7.05 ±1.64	4.99 ±1.41	6.18 ±2.04	<0.001
LH/FSH	1.22±0.43	1.46±0.73	2.00 ±0.82	<0.001
Prolactin (ng/mL)	10.37±4.85	13.87±5.41	18.84±3.91	<0.001
E <sub>2</sub> (pMol/L)	402.00±112.16	297.67 ±97.65	417.05±130.07	<0.001
T <sub>3</sub> (nmol/L)	1.86±0.99	1.73±0.56	1.67±0.40	0.52
T <sub>4</sub> (nmol/L)	95.05±23.68	87.67±22.44	81.66±26.67	0.08
TSH (mIU/L)	1.40±0.72	1.74 ±0.51	2.32 ±0.93	<0.001

**Fig 2:** Serum levels of hormones in normal-weight, overweight, and obese PCOS

### The person correlation coefficient analysis

In a Pearson correlation coefficient analysis for the overweight group, it was shown that there were some relationships between insulin resistance (HOMA-IR), body mass index (BMI), and several hormonal parameters. It was noted that the correlation of HOMA-IR with luteinizing hormone (LH) was weak and not significant (r=0.12, P=0.49).


The results also showed a negative and non-significant correlation between HOMA-IR and follicle-stimulating hormone (FSH) levels (r=-0.22, P=0.22), in contrast, a weak but significant negative correlation was recorded between BMI and FSH (r=-0.39, P=0.03). As for the LH/FSH ratio, it showed a modest positive correlation with HOMA-IR (r=0.19, P=0.23) and a non-significant negative correlation with BMI (r=-0.30, P=0.10).

For prolactin, there was no significant correlation with HOMA-IR ( $r=-0.07$ ,  $P=0.68$ ) or with BMI ( $r=0.11$ ,  $P=0.54$ ). Estradiol (E2) results revealed no significant correlation with HOMA-IR ( $r=-0.19$ ,  $P=0.32$ ) or BMI ( $r=-0.31$ ,  $P=0.09$ ). Thyroid hormones T<sub>3</sub> and T<sub>4</sub> did not show statistically significant associations in the study with HOMA-IR or BMI ( $r=-0.14$ ,  $P=0.43$  and  $r=-0.03$ ,  $P=0.83$  for T<sub>3</sub> respectively;  $r=-0.04$ ,  $P=0.80$  and  $r=-0.22$ ,  $P=0.24$  for T<sub>4</sub>

respectively). Finally, no significant correlation was observed between TSH and HOMA-IR ( $r=-0.13$ ,  $P=0.46$ ), but there was a non-significant negative correlation with BMI ( $r=-0.20$ ,  $P=0.27$ ). As expected, there was a perfect correlation between self-rated HOMA-IR ( $r=1$ ) and self-rated BMI ( $r=1$ ), indicating that the data on both HOMA-IR and BMI were internally consistent.

**Table 3:** The person correlation coefficient analysis of the overweight group.

		HOMA-IR	BMI (Kg/m <sup>2</sup> )
LH (mIU/mL)	<i>r</i>	0.12	-0.22
	<i>P</i>	0.49	0.22
FSH (mIU/mL)	<i>r</i>	0.13	-0.39*
	<i>P</i>	0.49	0.03
LH/FSH	<i>r</i>	0.19	-0.30
	<i>P</i>	0.23	0.10
Prolactin (ng/mL)	<i>r</i>	-0.07	0.11
	<i>P</i>	0.68	0.54
E <sub>2</sub> (pMol/L)	<i>r</i>	-0.19	-0.31
	<i>P</i>	0.32	0.09
T <sub>3</sub> (nmol/L)	<i>r</i>	-0.14	-0.03
	<i>P</i>	0.43	0.83
T <sub>4</sub> (nmol/L)	<i>r</i>	-0.04	-0.22
	<i>P</i>	0.80	0.24
TSH (mIU/L)	<i>r</i>	-0.13	-0.20
	<i>P</i>	0.46	0.27
HOMA-IR	<i>r</i>	1	0.15
	<i>P</i>		0.41
BMI (Kg/m <sup>2</sup> )	<i>r</i>	0.15	1
	<i>P</i>	0.41	



**Fig 3:** The person correlation coefficient analysis of the overweight group

### The person correlation coefficient analysis of the obese PCOS group

In a Pearson correlation coefficient analysis of the group with polycystic ovary syndrome (PCOS) and obese women, the table showed some correlations between levels of insulin resistance (HOMA-IR), body mass index (BMI) and various hormonal indicators. The research concluded that there was no significant correlation between luteinizing hormone (LH) levels and HOMA-IR ( $r=-0.22$ ,  $P=0.27$ ), but there was a significant negative correlation between LH and BMI ( $r=-$


$0.52$ ,  $P=0.02$ ). While it was found that there was no significant correlation between levels of follicle-stimulating hormone (FSH) and HOMA-IR ( $r=0.16$ ,  $P=0.39$ ) or BMI ( $r=0.13$ ,  $P=0.58$ ). As for the ratio between LH and FSH, it did not show a significant effect on HOMA-IR or BMI, as the results were ( $r=-0.03$ ,  $P=0.88$ ) for HOMA-IR and ( $r=-0.03$ ,  $P=0.90$ ) for BMI, respectively. Considering prolactin levels, no significant correlation was observed with HOMA-IR ( $r=-0.24$ ,  $P=0.19$ ) or BMI ( $r=-0.18$ ,  $P=0.34$ ). While estradiol (E2) levels were non-significantly positively

associated with HOMA-IR ( $r=0.29$ ,  $P=0.12$ ) as well as with BMI ( $r=0.21$ ,  $P=0.25$ ). Thyroid hormones  $T_3$  and  $T_4$  did not show significant correlations with HOMA-IR or BMI, as the results for  $T_3$  were ( $r=0.25$ ,  $P=0.17$ ) and ( $r=0.06$ ,  $P=0.71$ ) and for  $T_4$  the results were ( $r=-0.04$ ,  $P=0.80$ ) and ( $r=-0.08$ ,  $P=0.64$ ) respectively. No statistical significance was found for TSH levels with any of the variables with P values ( $r=-$

$0.05$ ,  $P=0.76$ ) for HOMA-IR and ( $r=0.00$ ,  $P=0.98$ ) for BMI. Finally, the analysis only showed a significant association between HOMA-IR and BMI in women with obesity and PCOS ( $r=0.42$ ,  $P=0.02$ ), adding evidence of a relationship between insulin resistance and the increase in BMI in this group.

**Table 4:** The person correlation coefficient analysis of the obese PCOS group.

		HOMA-IR	BMI (Kg/m <sup>2</sup> )
LH (mIU/mL)	<i>r</i>	-0.22	-0.52*
	<i>P</i>	0.27	0.02
FSH (mIU/mL)	<i>r</i>	0.16	0.13
	<i>P</i>	0.39	0.58
LH/FSH	<i>r</i>	-0.03	-0.03
	<i>P</i>	0.88	0.90
Prolactin (ng/mL)	<i>r</i>	-0.24	-0.18
	<i>P</i>	0.19	0.34
E <sub>2</sub> (pMol/L)	<i>r</i>	0.29	0.21
	<i>P</i>	0.12	0.25
T <sub>3</sub> (nmol/L)	<i>r</i>	0.25	0.06
	<i>P</i>	0.17	0.71
T <sub>4</sub> (nmol/L)	<i>r</i>	-0.04	-0.08
	<i>P</i>	0.80	0.64
TSH (mIU/L)	<i>r</i>	-0.05	0.00
	<i>P</i>	0.76	0.98
HOMA-IR	<i>r</i>	1	0.42*
	<i>P</i>		0.02
BMI (Kg/m <sup>2</sup> )	<i>r</i>	0.42*	1
	<i>P</i>	0.02	



**Fig 4:** The person correlation coefficient analysis of the obese PCOS group

## Discussion

This study compared endocrine hormones in obese PCOS patients, overweight people, and healthy weight controls. We also examined the relationship between BMI, HOMA-IR, and hormones in the overweight and obese PCOS groups. Obesity may cause insulin resistance in women with polycystic ovarian syndrome (PCOS) (Cassar *et al.*, 2016) [5]. Other pathways, such as insulin dysfunction due to insulin receptor signaling, are not fat-dependent. Elevated serine residue phosphorylation on insulin receptor substrate-1 impairs usual metabolic pathways in insulin-responsive

ovarian tissues, changing receptor signaling (Diamanti-Kandarakis & Dunaif, 2012) [18]. A 2016 study by Reyes-Muñoz *et al.* found insulin resistance (IR) in 60% of patients with polycystic ovarian syndrome (PCOS). These include 78.2% of obese women and 76.00% of non-obese women. The meta-analysis by Cassar *et al.* 2016 [5] indicated that 27% of women with polycystic ovarian syndrome (PCOS) worsen. A meta-analysis by Cassar *et al.* 2016 [5] indicated that 27% of PCOS women had impaired insulin sensitivity, a sign of insulin resistance. Insulin resistance was worsened by 15% of these women's higher BMIs (Cassar *et al.*, 2016)

[5]. This may be caused by obesity-related abdominal fat (Dumesic *et al.*, 2022) [20]. Overweight and obesity in women with PCOS exacerbate insulin resistance (IR), hyperinsulinemia, metabolic abnormalities, and reproductive characteristics (Barber *et al.*, 2019) [2]. The current investigation demonstrated a link between HOMA-IR and BMI in obese PCOS patients. Obesity was linked to HOMA-IR by Svensson *et al.* (2016) [56]. Weight gain also raised insulin resistance (IR) levels. Weight gain may increase insulin resistance due to altered MAPK and PI3K pathways (Makker *et al.*, 2012) [35]. The obese group with polycystic ovarian syndrome (PCOS) had higher HOMA calculator insulin resistance (IR) than the overweight and normal weight groups. This has been documented in multiple research (Dadachanji *et al.*, 2021) [11]. According to research, patients who have polycystic ovary syndrome and are obese or overweight have higher hormone levels than the control group, and this is what we found (Saleh & Al-Naddawi, 2022; Raju *et al.*, 2013) [50, 49]. After the ovulation period, the increase in androgen and progesterone levels may lead to a decrease in the secretion of GnRH, which leads to the secretion of FSH during the menstrual period, which leads to the growth of eggs during the second period of menstruation (Welt *et al.*, 2003) [60]. If GnRH is not slowed, FSH release will be reduced to a minimum (Chaudhari *et al.*, 2018) [6]. GnRH is not effectively inhibited by progesterone and estrogen, which may explain the increased LH levels and decreased FSH levels in females with PCOS (Haisenleder *et al.*, 1991) [25]. Therefore, due to the higher production of LH compared to FSH, the LH/FSH ratio is elevated in PCOS, leading to distinct hormonal markers. In addition, LH stimulates several steroidogenic enzymes in the theca cells of the ovary, promoting testosterone production (Hughesdon, 1982) [27]. Testosterone inhibits the normal feedback effects of progesterone and estradiol on the GnRH pulses, preventing LH surge and ovulation (Diamanti-Kandarakis & Dunaif, 2012) [18]. This study confirms previous research by Al-Fartosy *et al.* (2020) [66] and Chen *et al.* (2015) [7] that obese females with polycystic ovary syndrome (PCOS) have higher levels of oestrogen (E2) compared to those with normal weight.

According to Shaw *et al.* (2014) [52], increased activity of aromatase in granulosa cells may cause higher levels of estradiol in women with PCOS. Pituitary lactotroph cells secrete prolactin, and the promotion of this process is facilitated by oestrogen and dopamine receptors (DeVito *et al.*, 1992) [17]. Other studies have shown elevated levels of prolactin in females with PCOS compared to females without PCOS (Mahboobifard *et al.*, 2022) [34], consistent with the findings of the current study. Also, women with PCOS have increased GnRH pulsation, abnormal luteinizing hormone production, and decreased hypothalamic dopamine tone which may explain the increase in prolactin levels (Robin *et al.*, 2011; Delcour *et al.*, 2019) [13]. Other studies that have also shown a relationship between elevated LH and prolactin secretion in females with polycystic ovary syndrome (PCOS) and the ability of estrogen to enhance prolactin synthesis include (Venturoli *et al.*, 1988 and Christin-Maître *et al.*, 2007; and Azziz *et al.*, 2016) [59, 1, 10]. These studies concluded that elevated prolactin levels could serve as a diagnostic indicator for PCOS. Polycystic ovary syndrome patients with high male hormone levels

(hyperandrogenemia) and insulin resistance could develop thyroid dysfunction.

Raj *et al.*, 2021 [48] and Singh, 2020 [54] are referenced. In the current study, obese women with PCOS exhibited significantly higher TSH levels. Controlled ovarian hyperstimulation increased TSH levels in patients with adequate thyroid function, according to Noventa *et al.* 2021 [43]. The authors hypothesized that regulated ovarian hyperstimulation would enhance thyroxine-binding protein due to elevated E2. This would lower free thyroid hormones and raise serum TSH (Noventa *et al.*, 2021) [43]. Thus, we might infer that higher amounts of E2 in women with PCOS may influence thyroid hormones. In addition, Cai *et al.* 2019 [4] discovered that euthyroid-overweight women with polycystic ovary syndrome (PCOS) had higher levels of thyroid-stimulating hormone (TSH) above 2.5 mU/L. This finding is associated with hyperandrogenism, regardless of body mass index (BMI) (Cai *et al.*, 2019) [4]. Thyroid hormones play a role in the generation of androgens by influencing the activity of enzymes involved in steroid synthesis (Denver, 1988) [14]. Several studies have shown that the administration of a GnRH agonist is associated with changes in thyroid hormones (Du *et al.*, 2019; Han *et al.*, 2013) [19, 26]. Therefore, increased synthesis of GnRH in women with PCOS may have the ability to alter thyroid hormones at the pituitary gland. The results of our study support the previous findings that there is a negative correlation between LH levels and BMI in obese women with PCOS, which is in line with the data reported by Pagán *et al.* in 2006 [45]. The researchers determined that obesity alters the abnormal LH production patterns in females with PCOS specifically at the pituitary gland, rather than in the hypothalamus (GnRH) (Pagán *et al.*, 2006) [45]. The findings of Wu *et al.* (2022) [64] support our results, as they demonstrate an improvement in testosterone and LH hormone levels in obese persons with PCOS who undergo weight loss. Leptin, a major regulator produced by fat cells, may account for the increased serum levels observed in women with PCOS (Peng *et al.*, 2022) [46]. Several studies have demonstrated that women with polycystic ovary syndrome (PCOS) exhibit elevated levels of leptin, which are associated with body mass index (BMI) and luteinizing hormone (LH) levels (Jalilian *et al.*, 2016) [30]. However, other researchers were unable to establish a correlation between BMI and LH in persons with PCOS who are overweight or obese (Esmaeilzadeh *et al.*, 2015) [23].

The current study found that overweight people have lower FSH, LH, and E2 levels than normal-weight people. In the overweight cohort, FSH levels correlated negatively with BMI. Previous research reported reduced LH, E2, FSH, and inhibin B levels in overweight women. The study also found an inverse relationship between hormone levels and BMI. Weight inhibits gonadotropin and ovarian E2 production, according to studies (De Pergola *et al.*, 2006) [12]. Higher body weight increases leptin, which suppresses gonadotropin synthesis and E2 release by granulosa cells. Thus, overweight people may have higher leptin levels (Metwally *et al.*, 2007) [37], which may influence pituitary FSH release in proportion to BMI (Moschos *et al.*, 2002) [39]. More leptin research is needed to prove this notion.

## Conclusion

In light of our research, we can deduce that BMI substantially impacts the IR pathophysiology of Iraqi PCOS

women who are obese. Moreover, our findings suggest that BMI has a suppressive impact on FSH release in overweight women. Obesity impacts the irregular patterns of LH production in females with PCOS. BMI suppresses gonadotropin release across the two overweight and obese PCOS groups. A significant issue is that the study failed to find any relationship between IR and the studied hormones. As a result, we presume that IR seems to have no inhibitory/stimulatory activity on the pituitary-ovary and pituitary-thyroid axes.

### Ethical approval

Prior to the sample collection process, all patients participating in this study were duly informed and provided verbal consent. The study received approval from the Committee on Publication Ethics at the Martyr Mohammed Baqer Al-Hakim Hospital, Baghdad, Iraq.

### References

- Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, *et al.* Polycystic ovary syndrome. *Nature Reviews Disease Primers*. 2016;2(1):1-18.
- Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies. *Clinical Medicine Insights: Reproductive Health*. 2019;13:1179558119874042.
- Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. *Human Reproduction*. 2016;31(12):2841-55.
- Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J, *et al.* High thyroid stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: A cross-sectional analysis. *Frontiers in Endocrinology*. 2019;10:222.
- Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. *Human Reproduction*. 2016;31(11):2619-31.
- Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. *Reproductive Biology and Endocrinology*. 2018;16:1-13.
- Chen J, Shen S, Tan Y, Xia D, Xia Y, Cao Y, *et al.* The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. *Journal of Ovarian Research*. 2015;8(1):1-6.
- Chen X, Xiao Z, Cai Y, Huang L, Chen C. Hypothalamic mechanisms of obesity-associated disturbance of hypothalamic-pituitary-ovarian axis. *Trends in Endocrinology & Metabolism*; c2022.
- Choi J, Smitz J. Luteinizing hormone and human chorionic gonadotropin: Origins of difference. *Molecular and Cellular Endocrinology*. 2014;383(1-2):203-213.
- Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: Pregnancy, contraception and hormonal replacement therapy. *Gynecological Endocrinology*. 2007;68(2-3):106-12.
- Dadachanji R, Patil A, Joshi B, Mukherjee S. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. *PLoS One*. 2021;16(2):e0246862.
- De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R. Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. *Obesity Reviews*. 2006;14(11):1954-1960.
- Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: What do we know in 2019? *Clinical Medicine Insights: Reproductive Health*. 2019;13:1179558119871921.
- Denver RJ. Several hypothalamic peptides stimulate *in vitro* thyrotropin secretion by pituitaries of anuran amphibians. *General and Comparative Endocrinology*. 1988;72(3):383-393.
- Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. *British Journal of Nutrition*. 1991;65(2):105-114.
- Devins SS, Miller A, Herndon BL, O'Toole L, Reisz G. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. *Critical Care Medicine*. 1992;20(12):1644-1649.
- DeVito WJ, Avakian C, Stone S, Ace CI. Estradiol increases prolactin synthesis and prolactin messenger ribonucleic acid in selected brain regions in the hypophysectomized female rat. *Endocrinology*. 1992;131(5):2154-2160.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *Endocrine Reviews*. 2012;33(6):981-1030.
- Du YJ, Xin X, Cui N, Jiang L, Yang AM, Hao GM, *et al.* Effects of controlled ovarian stimulation on thyroid stimulating hormone in infertile women. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2019;234:207-212.
- Dumesic DA, Padmanabhan V, Chazenbalk GD, Abbott DH. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation. *Reproductive Biology and Endocrinology*. 2022;20:1-11.
- Elia EM, Bazzano MV, Quintana R, Paz DA. Reproductive disorders in obesity. *Global Journal of Health Science*. 2015;1(1):20-25.
- ESHRE, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*. 2004;81(1):19-25.
- Esmailzadeh S, Andarieh MG, Ghadimi R, Delavar MA. Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome. *Global Journal of Health Science*. 2015;7(2):101.
- Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. *Indian Journal of Endocrinology and Metabolism*. 2015;19(1):160.
- Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. A pulsatile gonadotropin-releasing

- hormone stimulus is required to increase transcription of the gonadotropin subunit genes: Evidence for differential regulation of transcription by pulse frequency *in vivo*. *Endocrinology*. 1991;128(1):509-517.
26. Han EJ, Do Song H, Yang JH, Park SY, Kim SH, Yoon HK, *et al*. Thyroid dysfunction associated with administration of the long-acting gonadotropin-releasing hormone agonist. *Endocrinology and Metabolism*. 2013;28(3):221-225.
27. Hughesdon P. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called hyperthecosis. *Obstetrical & Gynecological Survey*. 1982;37(2):59-77.
28. Itriyeva K. The effects of obesity on the menstrual cycle. *Current Problems in Pediatric and Adolescent Health Care*; c2022. p. 101241.
29. Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, *et al*. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. *The Journal of Clinical Endocrinology & Metabolism*. 2007;92(7):2468-2473.
30. Jalilian N, Haghazari L, Rasolinia S. Leptin and body mass index in polycystic ovary syndrome. *Indian Journal of Endocrinology and Metabolism*. 2016;20(3):324.
31. Jasim HM, Hussein HMA, Al-Kaseer EA. Obesity among females in Al-Sader city Baghdad, Iraq, 2017. *Journal of the Faculty of Medicine Baghdad*. 2018;60(2):105-107.
32. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. *American Journal of Physiology-Cell Physiology*. 2021;320(3):C375-C391.
33. Lim SS, Davies M, Norman RJ, Moran L. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. *Human Reproduction Update*. 2012;18(6):618-637.
34. Mahboobifard F, Rahmati M, Amiri M, Azizi F, Tehrani FR. To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study. *Advances in Medical Sciences*. 2022;67(1):79-86.
35. Makker A, Goel MM, Das V, Agarwal A. PI3K-Akt-mTOR and MAPK signalling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: An update. *Gynecological Endocrinology*. 2012;28(3):175-181.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor B, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28:412-419.
37. Metwally M, Li T, Ledger W. The impact of obesity on female reproductive function. *Obesity Reviews*. 2007;8(6):515-523.
38. Mikhael S, Punjala-Patel A, Gavrilova-Jordan L. Hypothalamic-pituitary-ovarian axis disorders impacting female fertility. *Biomedicine*. 2019;7(1):5.
39. Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: A review. *Fertility and Sterility*. 2002;77(3):433-444.
40. Ban M, Al Joborae S. Analysis of Patients with PCOS According to Demographic Factors & Hormonal Assay in Babylon Government in Iraq. *Journal of the Faculty of Medicine Baghdad*. 2020;20(2):473-478.
41. Nehir Aytan A, Bastu E, Demiral I, Bulut H, Dogan M, Buyru F. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. *Gynecological Endocrinology*. 2016;32(9):709-713.
42. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *The Lancet*. 2007;370(9588):685-697.
43. Noventa M, Riva A, Buzzaccarini G, Marin L, Sabbadin C, Bordin L, *et al*. Thyroid function in euthyroid women during controlled ovarian stimulation (COH): Does the TSH fluctuations have an impact on IVF outcomes? *Human Reproduction*. 2021;36(Supplement\_1):deab130-679.
44. Okati-Aliabad H, Ansari-Moghaddam A, Kargar S, Jabbari N. Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: A systematic review and meta-analysis. *Journal of Obesity*; c2022.
45. Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. An inverse relationship between the luteinizing hormone and body mass index in polycystic ovarian syndrome: Investigation of hypothalamic and pituitary contributions. *The Journal of Clinical Endocrinology & Metabolism*. 2006;91(4):1309-1316.
46. Peng Y, Yang H, Song J, Feng D, Na Z, Jiang H, *et al*. Elevated serum leptin levels as a predictive marker for polycystic ovary syndrome. *Frontiers in Endocrinology*; c2022, 13.
47. Perrett RM, McArdle CA. Molecular mechanisms of gonadotropin-releasing hormone signalling: Integrating cyclic nucleotides into the network. *Frontiers in Endocrinology*. 2013;4:180.
48. Raj D, Pooja F, Chhabria P, Kalpana F, Lohana S, Lal K, *et al*. Frequency of subclinical hypothyroidism in women with polycystic ovary syndrome. *Cureus*; c2021, 13(9).
49. Raju GAR, Chavan R, Deenadayal M, Gunasheela D, Gutgutia R, Haripriya G, *et al*. Luteinizing hormone and follicle-stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation. *Journal of Human Reproductive Sciences*. 2013;6(4):227.
50. Saleh BO, Al-Naddawi AM. Association between serum fructose level and insulin resistance in women with polycystic ovary syndrome: The effect of obesity. *Journal of the Faculty of Medicine Baghdad*. 2022;64(2):91-95.
51. Sayın S, Kutlu R, Kulaksızoğlu M. The relationship between sex steroids, insulin resistance and body compositions in obese women: A case-control study. *Journal of Medical Biochemistry*. 2020;39(1):25.
52. Shaw N, Srouji S, Welt C, Cox K, Fox J, Adams J, *et al*. Evidence that increased ovarian aromatase activity and expression account for higher estradiol levels in African Americans compared with Caucasian women. *The Journal of Clinical Endocrinology & Metabolism*. 2014;99(4):1384-1392.
53. Silvestris E, De Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. *Reproductive Biology and Endocrinology*. 2018;16:1-13.
54. Singh J, Wong H, Ahluwalia N, Go RM, Guerrero-Go MA. Metabolic, hormonal, immunologic, and genetic



- factors associated with the incidence of thyroid disorders in polycystic ovarian syndrome patients. *Cureus*; c2020, 12(11).
55. Supramaniam PR, Mittal M, McVeigh E, Lim LN. The correlation between raised body mass index and assisted reproductive treatment outcomes: A systematic review and meta-analysis of the evidence. *Reproductive Health*. 2018;15(1):1-15.
  56. Svensson H, Wetterling L, Bosaeus M, Odén B, Odén A, Jennische E, *et al.* Body fat mass and the proportion of very large adipocytes in pregnant women are associated with gestational insulin resistance. *International Journal of Obesity*. 2016;40(4):646-653.
  57. Tola H, Abbas M, Alhassan EA, Shrif NE, Rida M. Assessment of the role of the anti-mullerian hormone, luteinizing hormone/ follicle-stimulating hormone ratio in the diagnosis of polycystic ovary syndrome in Sudanese women. *Open Access Macedonian Journal of Medical Sciences*. 2018;6(7):1244.
  58. Tsutsumi R, Webster NJ. GnRH pulsatility, the pituitary response and reproductive dysfunction. *Endocrine Journal*. 2009;56(6):729-737.
  59. Venturoli S, Porcu E, Fabbri R, Magrini O, Gammi L, Paradisi R, *et al.* Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. *Clinical Endocrinology*. 1988;28(1):93-107.
  60. Welt CK, Pagan YL, Smith PC, Rado KB, Hall JE. Control of follicle-stimulating hormone by estradiol and the inhibins: Critical role of estradiol at the hypothalamus during the luteal-follicular transition. *The Journal of Clinical Endocrinology & Metabolism*. 2003;88(4):1766-1771.
  61. Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2020;13:3611.
  62. Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. *Circulation Research*. 2020;126(11):1549-1564.
  63. Wu L, Fang Q, Wang M, Wang Y, Zhu X, Fang Z. Effect of weight loss on pregnancy outcomes, neuronal-reproductive-metabolic hormones and gene expression profiles in granulosa cells in obese infertile PCOS patients undergoing IVF-ET. *Frontiers in Endocrinology*. 2022;13:954428.
  64. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: An updated review of pathogenesis, evaluation, and treatment. *Journal of Ovarian Research*. 2023;16(1):1-17.
  65. Al-Fartosy AJ, Awad NA, Alsalimi SA. Osteoprotegerin and some trace elements in type 2 diabetic patients with or without nephropathy: Effect of insulin resistance. *International Medical Journal*. 2020;25(4):1771-84.